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Co-stimulatory markersHuman monocytes are susceptible to dengue virus (DV) infection through an FcR-dependent pathway
known as antibody-dependent enhancement (ADE). In this study, infection enhancement was observed
when puriﬁed monocytes were infected with DV serotypes in the presence of serially diluted immune
serum antibodies. Analyzing binding of the DV-antibody immune complexes to monocytes by quantifying
the amount of viruses attached to monocytes, we found that binding did not correlate with the input amount
of antibodies; rather, it peaked at suboptimal antibody concentrations, correlating with the observed infec-
tion enhancement. These results suggested that immune complexes are involved in hindering DV from bind-
ing to FcR-bearing cells; when such a protective feature is weakened, enhancement of viral attachment and
ADE are observed. Further, increased cytokine production (TNF-alpha and IFN-alpha), and costimulatory
marker expression (CD86 and CD40), were found to be associated with infection enhancement, suggesting
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DV comprises 4 closely related but antigenically distinct serotypes
(1, 2, 3, 4) of arthropod-borne single stranded RNA viruses in the
genus ﬂaviviruses. All 4 serotypes cause a range of disease in humans, in-
cluding classic dengue fever (DF, acute febrile illness with headache,
body aches, and rash), dengue hemorrhagic fever (DHF), and the life-
threatening dengue shock syndrome (DSS) (Gubler, 1989; Halstead,
1988). Dengue is the second most important mosquito-borne disease
after Malaria. It is endemic throughout large parts of tropical andsubtropical regions of America and Asia. More than 2.5 billion people
in more than 100 endemic countries are at risk of infection. DHF/DSS
represents 2.5 to 20% of total hospitalized dengue cases, and is responsi-
ble for 30,000 deaths every year.
Typically, acute DF begins 5–7 days after a bite from an infectedmos-
quito. Viremia levels usually peak during the ﬁrst 3 days of the febrile
period, after which they decline rapidly. In most patients, as the viremia
declines, fever ends and a period of recovery follows; in a small percent-
age of patients, however, severe plasma leakage leads to clinical mani-
festations of thrombocytopenia, hypotension, and bleeding, which are
primary signs of DHF and DSS (Libraty et al., 2002; Srikiatkhachorn,
2009; Srikiatkhachorn et al., 2007; Vaughn et al., 2000).
One of themajor risk factors for DHF/DSS is the patient's previous ex-
posure to DV. Primary DV infections usually result in non-complicated DF
and the development of both humoral and cellular immunity; both are
long-term and protect the host from re-infection from the same serotype.
Although this anti-dengue immune response is cross-reactive in nature, it
does not confer long-term cross-protection to other serotypes. Instead, an
association of DHF with secondary infections was ﬁrst reported by Hal-
stead et al. in a group of Thai children in the 1960s (Russell et al.,
1967), and then observed in several other outbreaks in Cuba (Guzman
et al., 2002), and Southeast Asia (Kliks et al., 1988). A phenomenon
known as antibody-dependent enhancement (ADE) where immune
sera can enhance infection when diluted to suboptimal concentrations
(Goncalvez et al., 2007; Halstead et al., 2005; Moi et al., 2010) was dem-
onstrated in in vitro experiments. With ADE, cross-reactive non-
246 P. Sun et al. / Virology 421 (2011) 245–252neutralizing antibodies acquired from a previous (primary) infection can
mediate an enhancement of secondary heterologous infection through a
FcγR-dependent mechanism (Mathew and Rothman, 2008).
Histochemistry of autopsy samples from fatal dengue cases and in
vitro assays using peripheral blood cells revealed that macrophages/
monocytes are primary targets for DV infection (Jessie et al., 2004;
Kangwanpong et al., 1995). Macrophages/monocytes are potent phago-
cytic cells responsible for removing infectious pathogens. However,
they are often attacked by invasive pathogens. These cells express all
three classes of FcγR, (FcγRI, II and III) which serve as receptors for den-
gue virus entry in the forms of virus-antibody immune complexes. Ele-
vated levels of TNF-α, a cytokine produced by activated monocytes,
have been detected in DHF/DSS patients (Hober et al., 1993; Nguyen
et al., 2004; Vitarana et al., 1991). In this study, functional aspects of
ADE-affected monocytes, cell activation and cytokine production, were
characterized in order to allow a better understanding of the role of
ADE and monocytes in the pathology of DHF.
In an in vitro model, infection enhancement was investigated using
puriﬁed primary monocytes from random healthy blood donors and
serum IgG antibodies puriﬁed froma human subjectwhowas previous-
ly exposed to DV3 (D3IgG). Infection enhancement of DV3 andDV1was
observed at different antibody concentrations. A positive correlation
was observed between the magnitude of ADE levels and cell activation
and cytokine secretion.
Results
ELISA and neutralization activity of the puriﬁed D3IgG
The serotype cross-reactivity of the puriﬁed D3IgG was evaluated by
ELISA andneutralization assay. ELISA result showed that theD3IgG bond
to both DV3 and DV1 with signiﬁcantly higher O.D. values (Fig. 1a)0
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Fig. 1. ELISA and neutralization measurement for D3IgG and ControlIgG. Puriﬁed IgG
antibodies from a dengue serotype-3 immune subject (D3IgG, close symbol) and a den-
gue non-immune subject (ControlIgG, open symbol) were tested for binding (a) and
neutralization activities (b) to DV1 (circle symbol) and DV3 (triangle symbol) respec-
tively. The neutralization assay was performed using a L-SIGN Raji cell line. The NT50
for the D3IgG on DV3 is 44.compared to the control IgG, suggesting that D3IgG is capable to bind
to both DV3 and DV1. By contrast, neutralization activity of the D3IgG
against DV3 and DV1 was clearly different (Fig. 1b). No neutralization
activitywas seenwithDV1. Using non-linear regression, a neutralization
titer-50 (NT50) of 44 was obtained, meaning that at D3IgG dilution of
44, the antibodies are capable to reduce 50% of DV3 infection. The con-
trol IgG did not show any binding in ELISA, nor infection neutralization.
D3IgG-mediated enhancement of infection in human monocytes
Infection enhancement experiments were set up using serially dilut-
ed D3IgG and the control IgG. Infection of monocytes by DV alonewith-
out the presence of the D3IgG (corresponding to antibody concentration
of 0) was set as the infection baseline from which infection enhance-
ment was determined. As shown in Figs. 2b and c, infection baselines
for both DV1 and DV3 were low: 1.03% for DV1 from an average of 10
donors, and 0.13% for DV3 from an average of 3 donors, indicating that
very few cells were directly infected by DV. Infection enhancement to
heterotypic serotype DV1 was readily detected with undiluted D3IgG
and peaked at antibody dilution of 1:9 (14.41%), showing a N14 fold en-
hancement. On the other hand, infection enhancement with the homo-
typic serotype DV3 (Fig. 2b) was not seen in the presence of higher
antibody titers (from 1 to 1:27); infection enhancement appeared at
lower antibody titers (1:81–1:243). The highest infection rate was
0.86%, a 6.6 fold enhancement above the baseline. Interestingly, for
this particular case, the peak ADE (1:81) for DV3 appeared when neu-
tralization antibody titers were below 44, the titer of NT50.
The L-SIGNdetectionmethod thatmeasures viruses in the culture su-
pernatants showed a similar pattern of infection enhancement (Figs. 2d
and e). Infectious virus titers in culture supernatants increased from 24 h
to 48 h post-infection. For DV1, infectious virus titers in culture superna-
tants declined from 48 h to 72 h. Due to the shortage of monocytes, we
were unable tomeasure supernatant virus titers for DV3 at 72 h post-in-
fection. Results suggested that antibody enhancement of DV infection on
FcγR-bearing cells is dependent on antibody titers and virus serotypes.
Immune complex binding to monocytes
The initial step that leads to an infection is the formation of virus–
antibody immune complexes and binding the immune complexes to
FcγR on target cells. By quantifying the amount of viruses attached to
monocytes, we were able to indirectly evaluate the amount of DV-anti-
body immune complexes bond to monocytes. The quantitative mea-
surement of viruses was done by measuring the amount of viral RNA
copy numbers in a qPCR method. For binding assay, cells exposed to
virus alone (antibody concentration of 0) were set as assay baselines.
As shown in Fig. 3, the peak of DV3 binding was at IgG dilution of
1:27, which was slightly miss-matched with the peak of infection en-
hancement of 1:81 (Figs. 2b and d); the peak of binding of DV1 (1:9)
waswell-matchedwith infection enhancement (Figs. 2c and e). Regard-
less, the virus binding curves (Fig. 3) showed an overall similar trend
with the infection enhancement curves (Fig. 2): the highest binding ac-
tivity corresponded to the suboptimal concentrations of D3IgG. For the
control IgG, baseline binding was detected, but no signiﬁcant enhance-
ment of bindingwas observed at any concentration. In all of the binding
experiments performed, untreated monocyte or monocytes treated
onlywith immune antibodies (Mock control) showed 0 RNA copy num-
bers in qPCR (data not shown).
Cytokine production
As shown in Fig. 4, monocytes infectedwith either DV3 or DV1 alone
without the treatment of D3IgG (IgG dilution of 0) did not signiﬁcantly
show cytokine production; higher amounts of cytokine production cor-
responded to infection enhancement. While TNF-α, IFN-α and IL-10
production was all detected from DV1 ADE-affected monocytes during
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Fig. 2. Infection enhancement in monocytes. a) Dot plot images showing infected monocytes. Infected cells were directly stained with a ﬂuorescent monoclonal anti-dengue antibody
2H2. b–e) Infection enhancement of monocytes with DV3 and DV1 in the presence of serially diluted D3IgG (close symbols) and ControlIgG (open symbols). For the x-axis, the ﬁrst
mark, 1, represents undiluted IgG,whereas 0 represents no IgG control. Infectedmonocyteswas directly detected by immunoﬂuoresecent stainingwith anti-denguemonoclonal antibody
2H2 and percentages of infectedmonocytes detected by 2H2 48 h post infection were shown (b, c). Background staining (monocytes treatedwithMock antigen at each IgG dilution)was
subtracted. The supernatants collected frommonocyte cultures at 24, 48 and 72 h post-infection from the same sets of experiments shown in b and c were tested on L-SIGN Raji cells. The
percentages of infected L-SIGN Raji cells were shown (d, e). Background staining (themock control)was subtracted. Data for c and ewere a summary of 10 experiments usingmonocytes
from 10 different subjects. Data for b and d were a summary of 3 experiments. Error bars representing SEM.
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Fig. 3. Assessing the amount of immune complex binding to monocytes using DV RNA copy numbers by the qPCRmethod. Serotype of DVwas indicated. Data is from one experiment to
represent more than 3 experiments. Cells treated with mock antigen and serially diluted IgG showed 0 RNA copies (data not shown).
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Fig. 4. Cytokine production by infected monocytes. Monocytes were infected with DV1 or DV3 in the presence of serially diluted D3IgG (close symbols) and ControlIgG (open sym-
bols). Supernatants from monocyte cultures were collected for cytokine detection at 3 time points, 24 24 (        ) , 48 48 (        ) and 72 72 (        ) h post infection. X-axis shows serial
dilutions of IgG where 1 represents undiluted IgG and 0 represents no IgG control. Data from cells treated with mock antigen and serially diluted IgG was subtracted. Data was
summarized from 3 experiments with error bars representing SEM.
248 P. Sun et al. / Virology 421 (2011) 245–252the whole assay period (24–72 h post-infection), the highest cyto-
kine production was seen at 48 h post-infection. TNF-α and IFN-α
production was also seen in DV3 ADE-affected monocytes at 48 h
post-infection. No IL-10 was detected in DV3 infected monocytes.
No cytokine production was seen with the control IgG.
Costimulatory markers on ADE-affected monocytes
As shown in Figs. 5a and b, CD86 and CD40 were upregulated on
monocytes treated with DV1 and D3IgG after 2 days of infection.
The kinetics of CD86 and CD40 expression corresponded to the kinet-
ics of infection enhancement (shown in Fig. 2). Cells treated with an-
tibodies alone, and cells treated with DV1 and the control IgG did not
show upregulation of these markers.
Discussion
Antibodies elicited by dengue infectionmay play dual roles: blocking
infection through a mechanism of antibody neutralization or enhanceviral infection via a phenomenon of ADE. Characterizing the functional
nature of dengue immune sera has been an ongoing effort for research
and vaccine development. The phenomenon of ADE has been investigat-
ed in vitrowith a variety of cell types, THP-1 humanmonocytic leukemia
cell line (Chareonsirisuthigul et al., 2007; Diamond et al., 2000; Fust,
1997), K562 human erythroleukemia cell line (Guy et al., 2004; Littaua
et al., 1990), and primary human dendritic cells (Boonnak et al., 2008).
In this study, we chose to use primary bloodmonocytes in an in vitro in-
fectionmodel to study ADE.Monocytes are precursors ofmacrophages in
tissues. Monocytes and monocyte-derived macrophages are scavenging
and antigen-presenting cells, and they secrete cytokines, chemokines,
growth-regulatingmolecules; they are actively involved inmany inﬂam-
matory diseases, such as autoimmune diseases, bacterial and viral infec-
tious diseases, etc. The abundance of monocytes in human peripheral
blood (about 30% of human PBMCs) suggested the potential importance
of these cells for dengue infection and disease pathogenesis.
Monocytes are prime targets for DV replication in vivo (Blackley et al.,
2007; Jessie et al., 2004; Kangwanpong et al., 1995). Besides FcγR,mono-
cytes express mannose receptor, a member of C type lectin, shown to
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Fig. 5.Monocyte activation markers. Monocytes were infected with DV1 in the presence of D3IgG (close symbols) and ControlIgG (open symbols). Cells were collected after 48 h of
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249P. Sun et al. / Virology 421 (2011) 245–252bind all 4 serotypes of DV (Kliks et al., 1989). Another C-type lectin, DC-
SIGN (Dendritic Cell-Speciﬁc Intercellular adhesionmolecule-3-Grabbing
Non-integrin), abundantly expressed on human immature myeloid line-
age dendritic cells, is also characterized as a receptor with high binding
afﬁnity to all 4 serotypes of DV (Tassaneetrithep et al., 2003). For cells
that express both FcγR and DC-SIGN, such as human dendritic cells, DC-
SIGN seem to interfere with FcγR-mediated virus uptake (Boonnak
et al., 2008; Marovich et al., 2001). Only when DC-SIGN expression on
dendritic cells was reduced, ADE phenomenon appeared. Unlike human
dendritic cells,we found that infectingmonocytes through cell surface re-
ceptor such as mannose receptors was not efﬁcient, but through FcγR
was muchmore efﬁcient. Using DV1 as an example, among 10 randomly
selected donors, without the presence of antibodies, an average of 1.03%
monocytes was infected. In the presence of D3IgG, there was an average
of 14.41% (N14 fold increase) infection. The results suggested that mono-
cytes may be poor target cells in primary infections, but they may play a
prominent role in secondary infections (Durbin et al., 2008; Kou et al.,
2008).
Infection of human monocytes requires the presence of antibodies;
therefore, FcγR expressed on the monocyte surface is the key receptor
molecule for viral binding and entry in the form of antibody–DV im-
mune complex. Since FcγR has high binding afﬁnity to immune com-
plexes than to free antibody molecules, we asked if there existed a
relationship between antibody concentration and immune complex
binding under a ﬁxed amount of viruses, and how these factors would
affect infection enhancement. Immune complex binding wasmeasured
indirectly by quantitating the amount of viruses bound to monocytes.
We found that binding of the immune complexes does not necessarily
correspond to input amount of antibodies, rather, the peak of immune
complex binding was at suboptimal concentrations of antibodies. Com-
paring the infection curves (Fig. 2) with the binding curves (Fig. 3), we
found that they shared a similar trend. However, while binding (Fig. 3b)
and infection of DV1 (Figs. 2c and d) seemed to peak at the same anti-
body dilution, the binding and infection curves of DV3 appeared to be
slightly mismatched: the binding peaked at 1:27 (Fig. 3a) whereas the
infection peaked at 1:81 (Figs. 2b and d). This may reﬂect the complex
nature of serum antibodies. A dengue immune serum is a mixture of
neutralization and enhancement antibodies. Based on several well-
documented theories regarding molecular mechanisms of antibody
neutralization (Burton et al., 2000, 2001; Diamond et al., 2008; Klasse
and Sattentau, 2002; Oliphant et al., 2006; Pierson et al., 2007), antibody
neutralization can occur at several levels: 1) blocking the virus from
attaching to the receptors; 2) deactivating the virus by targeting to crit-
ical functional molecular spots which are essential for the replicationcycle of the virus, for example, binding to the fusion peptide (a se-
quence on domain II of dengue E protein), thus hindering the virus–
host cell membrane fusion process; and 3) hindering other replication
steps inside the host cells (Burton et al., 2001). The imperfectmismatch
between the binding and infection curves of DV3 may suggest that in-
fection enhancement is determined not only by the amount of viral
binding, but also by a delicate balance of other serum neutralization
and enhancement activities. Since the immune serum used for this
study is from a DV3 immune donor. This serum contains neutralization
antibodies to DV3, but not to DV1 (Fig. 1). Therefore, it is understand-
able that binding of DV3 did not immediately result in infection.
The FcγRs are distributed throughout the immune system, particu-
larly on effector cells of the innate immune system, such asmacrophage,
monocytes, and dendritic cells (Ravetch and Bolland, 2001). The binding
of the immune complexes to FcγRs provides powerful triggering signals,
leading to an activation of these effector cells. FcγR play important roles
in the pathophysiology of autoimmune diseases and hypersensitivity
(Ravetch and Bolland, 2001). We showed that production of IL-10,
TNF-α and IFN-α frommonocyte cultures correlated with the enhance-
ment of infection. These cytokines were nearly undetectable when in-
fection of monocytes was done without the antibodies. TNF-α is a
pluripotent vasoactive immunomodulator. DHF diseases have been sug-
gested to be a consequence of immunopathology caused by overproduc-
tion of inﬂammatory mediators (Hober et al., 1993; Nguyen et al., 2004;
Rothman, 2004). Increased serum and plasma TNF-α in patients with
DV infection were reported (Hober et al., 1993; Vitarana et al., 1991).
Relatively higher levels of TNF-α have been detected in ethnic Thai pa-
tients with DHF, compared with patients with DF. Single nucleotide
polymorphism of TNF gene allele ismore frequently detected in DHFpa-
tients of secondary infections (Fernandez-Mestre et al., 2004). Likewise,
IFN-α was detected in both DHF and DF patients' sera of Thai children:
higher percentages of DHF children had detectable serum IFN-α com-
pared to DF children. Taken together, these observations emphasized
the role of monocytes in secondary dengue infections. Although mono-
cytes can be activated during primary infections, theymight be poor cy-
tokine secreting cells.
The fundamental mechanism underlying severe dengue clinical
manifestations (bleeding, thrombocytopenia and shock) is vesicular
leakage. It is possible that a complex interaction between virus and
host immune response plays roles to impact the vesicular endothelial
barrier integrity, leading to plasma leakage (Mathew and Rothman,
2008; Srikiatkhachorn, 2009). Endothelial cell permeability in the con-
text of dengue infection has been studied in vitro using human umbilical
vein endothelial cells (HUVEC) (Dewi et al., 2004). TNF-α at 1 and
250 P. Sun et al. / Virology 421 (2011) 245–2520.1 μg/ml increased HUVAC permeability, but TNF-α at lower dose did
not. However, another study showed that high dose of TNF-α alone
did not affect HUVAC cell permeability; TNF-α in combination with cy-
tokines produced by T cells played a role on HUVAC cell permeability
(Seynhaeve et al., 2006). Our future effort will be focused on under-
standing how cytokines and cellular immune responses impact endo-
thelial cell permeability and vesicular leakage.
In addition, we examined monocyte activation and found that co-
stimulatory markers which are important for T cell stimulation were
up-regulated on ADE-affected monocytes. A study aimed to deﬁne pri-
mary cell types permissible to DV infection within PBMCs of endemic
children naturally infectedwith dengue found that activatedmonocytes
(CD14+CD11c+CD32+CD86+CD4−CD8−) were the primary cell
type in which DV antigen was detected. A higher percentage of PBMCs
from DHF patients co-expressed DV antigen, CD86, CD32, and CD11c
than did those from DF patients, indicating that increased activation of
monocytes and greater numbers of DV-infected cells were associated
with more severe dengue illnesses (Durbin et al., 2008). Our in vitro
data showing ADE-affected monocytes have elevated CD86 and CD40
expression not only supported this study, but also provided explana-
tion: increased infection through ADE caused CD86 upregulation and
cell activation. CD86 and CD40 are costimulatory molecules expressed
mainly on antigen-presenting cells such as monocytes, macrophages,
dendritic cells, and B cells. Inﬂammatory cytokines, TNF-α and IFN-α,
can act synergistically with antigens to promote the expression of
these costimulatory markers (Steinbrink et al., 2000). Therefore, it is
possible that higher levels of CD40 and CD86 expression in ADE-affect-
ed monocytes maybe a consequence of increased exposure to both of
the antigens and inﬂammatory cytokines. Further, CD40 and CD86 are
costimulatory markers important for T cell activation. Higher levels of
soluble markers of cellular immunity including TNF-α, IL-2 receptors
and CD8 were found in sera of patients with more severe disease;
higher levels of activated DV-speciﬁc CD8+ T cells were found in pa-
tients of more severe disease; increased production of both Th1 and
Th2 cytokines were found during acute disease (Libraty et al., 2002;
Rothman, 2003). Theseﬁndings suggest that T cells play a role in disease
pathogenesis. Increased expression of cytokine and costimulatory
markers on ADE-affected monocytes may increase T cell activation,
thus contribute to disease severity.
In conclusion, monocytes can be more efﬁciently infected through
FcγR-dependent mechanism than through cell-receptor such as man-
nose receptors. In response to ADE, monocytes produced high levels
of IFN-α and TNF-α and expressed higher co-stimulatory markers. We
think that they play a more prominent pathological role in secondary
infections than in primary infections. On the other hand, pre-existing
serum antibodies can block viruses, protecting FcγR-bearing cells
from DV infection. Future investigations into how to augment the anti-
bodies-neutralization of FcγR-bearing cells, by serum complements or
byusing syntheticmolecules that can change the course of phagocytosis
and its down-stream cellular signaling cascades, are the keys for mini-
mizing immune enhancement.
Materials and methods
Virus preparation
DV1 strain West Pac 74 and DV3 strain CH53489 were grown and
propagated in mycoplasma-free Vero cell culture. The viral titers were
determined by limiting-dilution plaque assay on Vero cells. If not specif-
ically stated, both viruses were used at titers of 3×106 PFU/ml. The
infecting MOI at this concentration was close to 1.
Medium
Sterile Complete Lymphocyte Medium was prepared as following:
RMPI 1640 w/o L-Glutamine (Mediatech) supplemented with 1% ofPenicillin 10,000 IU/ml and Streptomycin 10,000 μg/ml (Invitrogen),
10% Heat-inactivated Fetal Bovine Serum (Quality Biologics), 1%
L-glutamine 200 mM in 0.85% NaCl, and 1% Non-essential Amino
Acid (Mediatech).
Monocyte preparation
Human peripheral blood from unidentiﬁed healthy donors was
obtained under an approved human use protocol NMRC.2007-0009. Pe-
ripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Hypaque (GE Healthcare) density gradient centrifugation. CD14+
monocytes were positively selected fromwhole PBMCs using magnetic
microbeads for CD14 isolation (Miltenyi Biotec). After isolation, CD14+
cells were placed overnight in 96-well plate (2×105 cells/well) at 37 °C
in a 5% CO2 incubator before being used for ADE experiments.
Puriﬁcation of serum IgG
The IgGwas puriﬁed from a DV3-immune serum and a dengue non-
immune serum (obtained through the approved human use protocol
NMRC.2007.2009) using IgG puriﬁcation columns and Protein G
coupled agarose. Brieﬂy, 15 ml columonocytess (Pierce) were packed
with 5 ml of Immobilized protein G plus (Thermo Fisher Scientiﬁc).
The human serum was diluted 1:2 with Binding/Wash buffer (Pierce)
and allowed to bind to the Protein G during 2 h incubation period at
room temperature. Unbound substances were washed away with
15 ml of wash buffer. The bound IgG was eluted with 15 ml of gentle
elution buffer. Puriﬁed IgG was ﬁrst dialyzed in Tris-buffered saline for
24 h, to be followed by another 24 h dialysis in Phosphate-buffered sa-
line using 15–30 ml slide-a-lyzer dialysis cassettes (Pierce). The dia-
lyzed IgG was then concentrated by utilizing Millipore concentration
columonocytess. The concentration was recorded using spectropho-
tometer reading at 280 nm.
ELISA and antibody neutralization assay
The binding and the neutralization activity of the D3IgG to DV3 and
DV1weremeasured as previously described (Kochel et al., 2000;Martin
et al., 2006). Brieﬂy, 96-well ELISA plate was coated with DV1 and
DV3 respectively and serially diluted D3IgG was added. The plate was
developed following common procedures of ELISA and the binding
was scaled by optical density (O.D.) values. For neutralization assay,
30 μl/well of serially diluted D3IgG was cocultured with 30 μl/well of
DV at 37 °C. After 30 min incubation, 60 μl/well of liver/lymph node-spe-
ciﬁc intercellular adhesion molecule-3-grabbing integrin (L-SIGN)
transfected Raji cells were added to the plate which was then placed
into the 37 °C 5% incubator for 20 h. Infection was determined by
intracellular immuno-ﬂuorescent staining using a dengue group speciﬁc
monoclonal antibody, 2H2. The neutralization activity was shown as
reduction of infection at each D3IgG concentration on the bases of an
infection control which was set as infection without the interference of
any serum.
ADE experiment setup
DV was co-incubated with serially diluted D3IgG at a ratio of 20 μl
D3IgG and 80 μl of virus for 30 min at 37 °C in a 5% CO2 incubator allow-
ing the formation of immune complexes. Mock controls were set up the
sameway, but Vero cell supernatant containing no viruses were used to
replace DV. Following the incubation period, 100 μl of the DV (orMock)
and antibody mixtures was transferred onto monocytes and incubated
for 3 h at 37 °C in a 5% CO2 incubator. Cells were washed twice with
plain RPMI 1640 and once with complete growth media (CM). At the
end of 3 washes, 200 μl of CM was added to the plate and the cultures
were placed in 37 °C 5% CO2 incubator for 3 days. Monocyte cultures
251P. Sun et al. / Virology 421 (2011) 245–252and supernatants were collected at times for assessment of infectivity
and cytokines.
Detection of DV-infection in monocytes and in culture supernatants
Viral infectionwasmeasured directly inmonocytes and inmonocyte
culture supernatants. Brieﬂy,monocytes were harvested, ﬁxed and per-
meabilized using a Perm/Fix kit (BD). After staining the cells intracellu-
larlywith ﬂuorescent 2H2 for 30 min, percentage of infectedmonocytes
was determined by immuno-ﬂow cytometry. Infectious progeny virions
that were produced by infected monocytes into the culture superna-
tants were quantiﬁed using a Raji cell line expressing L-SIGNmolecules.
In a 96-U-bottomed plate, 50 μl of monocyte culture supernatants was
cultured with 50 μl L-SIGN Raji cells containing 5×105 cell counts.
After 24 h of incubation for DV1 supernatants and 48 h for DV3 super-
natants, percentage of infected L-SIGN cells was determined by intracel-
lular staining of 2H2 antibodies and immuno-ﬂow cytometry.
Binding assay
Binding of DVwas performed as previously described (Takhampunya
et al., 2009). Brieﬂy, D3IgG was co-incubated with DV for 30 min at 4 °C.
Before the addition of D3IgG–DV mixtures, monocytes were chilled on
ice for 30 min. Cells were incubated with D3IgG–DV mixture for 1.5 h
at 0 °C (binding assay) in serum-free RPMI 1640 medium containing
minimumessential amino acids (1%), L-glutamine (1%), sodiumpyruvate
(1%), and Penicillin/Streptomycin (1%). Binding of DV to monocytes was
quantitated by qPCR and results were presented as DV RNA copy #.
Quantitative PCR for measurement of DV positive sense RNA copies
The positive sense RNA copy numberswere determined by Quantita-
tive PCR using reaction conditions modiﬁed from a PCR assay described
previously (Callahan et al., 2001). Brieﬂy, the following primer sequences
were used:
Forward primer: AAG GAC TAG AGG TTA KAG GAG ACC C
Reverse primer: GGC GYT CTG TGC CTG GAW TGA TG
Flouregenic probe: FAM– AAC AGC ATA TTG ACG CTG GGA GAG
ACC –TAMRA
This probe recognizes Dengue serotypes 1 and 3 only. The probes
were labeledwith FAM as the ﬂourophore and TAMRA as the quencher.
The reactionwas carried out using a TaqMan EZ-RT PCR kit with the fol-
lowing ﬁnal reagent concentrations: 1× TaqMan Buffer, 0.1 Units/μl of
Recombinant Tth DNA Polymerase, 0.1 mM of dNTP's, 0.15 μM probe,
0.75 μMof forward primer, 0.75 μMof reverse primer, 115 mMof Potas-
sium Chloride (KCl) and 3 mM of Manganese Acetate. The assay was
run on an ABI 7000 (Applied Biosystems) using the following cycling
conditions: One 30 minute reverse transcription step at 60 °C followed
by 45 cycles of a 95 °C denaturation step lasting 15 s and a 60 °C exten-
sion step lasting 30 s.We used a housekeeping geneβ-actin as a loading
control in every experiment (Pfafﬂ, 2001).
Cytokine production in culture supernatants
IFN-αwas measured by ELISA, according to the manufacturer's rec-
ommendations (PBL Biomedical Laboratories). Samples were read on a
SpectraMax 340 plate reader (Molecular Devices). All other cytokines
were quantiﬁed by BD inﬂammatory cytometric bead array (CBA) kit
on FACScan or FACSArray using CBA software (BD Pharmingen).
Expression of co-stimulatory markers
Monocyte co-stimulatory marker expression was determined using
monoclonal antibodies, CD86 (BD), CD40 (Beckman Coulter) and HLA-A, B, C (BD). Staining of these markers was performed after 48 h post
infection.
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